Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,250.00 at Daiwa Securities Group

Eli Lilly and Company (NYSE:LLY) had its price objective increased by stock analysts at Daiwa Securities Group from $1,230.00 to $1,250.00 in a note issued to investors on Wednesday,MarketScreener reports. The brokerage presently has a “buy” rating on the stock. Daiwa Securities Group’s target price would suggest a potential upside of 22.82% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Deutsche Bank Aktiengesellschaft boosted their price objective on Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the company a “buy” rating in a research note on Monday, February 9th. TD Cowen increased their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Finally, Rothschild & Co Redburn increased their target price on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a report on Monday, January 26th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,219.68.

Eli Lilly and Company Trading Down 1.8%

Shares of LLY traded down $18.31 during trading on Wednesday, reaching $1,017.74. 371,301 shares of the company traded hands, compared to its average volume of 3,311,740. The stock has a market cap of $960.10 billion, a PE ratio of 44.36, a price-to-earnings-growth ratio of 1.21 and a beta of 0.39. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock has a 50-day simple moving average of $1,054.36 and a 200-day simple moving average of $912.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period last year, the business posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in the business. 10Elms LLP grew its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. grew its position in shares of Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after acquiring an additional 10 shares in the last quarter. Tanager Wealth Management LLP increased its stake in Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC raised its stake in Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after acquiring an additional 10 shares during the period. Finally, Wealthspan Partners LLC lifted its holdings in shares of Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after purchasing an additional 10 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CSL signed an exclusive licensing agreement with Lilly for clazakizumab, giving Lilly broader rights to develop/commercialize a therapy for complications in end‑stage kidney disease — a near‑term revenue and partnership positive. CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
• Positive Sentiment: Retevmo showed improved event‑free survival in early‑stage non‑small cell lung cancer and is moving into adjuvant settings — expands label opportunity and adds oncology revenue optionality. Lilly’s rare cancer drug Retevmo looks to broaden reach with adjuvant trial win
• Positive Sentiment: Clinical data reports show Lilly’s experimental lung‑cancer therapy cuts recurrence risk in early‑stage patients — promising efficacy that could support future approvals and uptake. Eli Lilly’s Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients
• Positive Sentiment: Lilly is building supply (reported ~$1.5B inventory) ahead of an expected oral obesity pill approval and planning a global launch, reducing the risk of early shortages that hurt past launches. Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill
• Positive Sentiment: Lilly outlined a $1B investment to build India manufacturing/export capacity, supporting global supply and potentially lowering manufacturing costs long term. Lilly targets India as global export hub amid booming Mounjaro sales, executive says
• Positive Sentiment: Lilly is committing ~ $1B to AI and advanced R&D approaches, which investors view as a long‑term catalyst for faster drug discovery and higher pipeline value. Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery
• Neutral Sentiment: Market commentary notes rising competition in obesity — Lilly’s next‑gen oral orforglipron and retatrutide face intensifying rivals, which could compress future pricing/margin upside if competitive dynamics worsen. Can LLY’s Next-Gen Obesity Pipeline Sustain Growth Amid Competition?
• Neutral Sentiment: Brand/marketing moves such as naming Shaquille O’Neal an ambassador for a Team USA recovery program raise awareness but have limited direct financial impact. Basketball legend Shaquille O’Neal named ambassador for Team USA Athlete Recovery Program in partnership with Eli Lilly
• Neutral Sentiment: Investor events: Lilly confirmed participation in TD Cowen’s health‑care conference (CFO fireside chat), which may provide more management updates but is routine. Lilly to participate in TD Cowen’s 46th Annual Health Care Conference

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.